Evidence map›Paper›PMID 39056532›Full record

ReviewPediatric pulmonology2024

Cystic fibrosis year in review 2023.

David V Swetland, Adrienne P Savant

Abstract readReview
In one paragraph

Review in Pediatric pulmonology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Cystic fibrosis year in review 2023.Pediatric pulmonology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David V SwetlandDepartment of Pediatrics, Children's Hospital of New Orleans, New Orleans, Louisiana, USA.ORCID 0000-0002-7851-5819
Adrienne P SavantDepartment of Pediatrics, Children's Hospital of New Orleans, New Orleans, Louisiana, USA.ORCID 0000-0003-3909-9477

Funding

None
6 · The paper itself

Abstract

This past year, there were many important advances for patients with cystic fibrosis (CF). Of the many publications related to CF in 2023, there was further evaluation of highly effective modulator therapy, new assessments and guidelines for clinical manifestations and therapies for CF, advances in newborn screening and diagnosis, and evaluation of outcomes for people with CF transmembrane conductance regulator-related metabolic syndrome/CF screen positive, inconclusive diagnosis. The aim of this review article is not to provide a full assessment of the wide range of articles published in 2023, but to provide a brief review of publication that may lead to changes in clinical care.

Indexed as

Cystic FibrosisNeonatal ScreeningCystic Fibrosis Transmembrane Conductance RegulatorHumansInfant, NewbornCystic Fibrosis Transmembrane Conductance RegulatorCFTR modulatorscystic fibrosishepatobiliarynewborn screeningpulmonary exacerbations

Identifiers

PMID39056532
PMCPMC11601032

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.